925 related articles for article (PubMed ID: 27158275)
1. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
[TBL] [Abstract][Full Text] [Related]
2. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
3. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.
Reifenberger G; Hentschel B; Felsberg J; Schackert G; Simon M; Schnell O; Westphal M; Wick W; Pietsch T; Loeffler M; Weller M;
Int J Cancer; 2012 Sep; 131(6):1342-50. PubMed ID: 22139906
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.
Christians A; Hartmann C; Benner A; Meyer J; von Deimling A; Weller M; Wick W; Weiler M
PLoS One; 2012; 7(3):e33449. PubMed ID: 22428052
[TBL] [Abstract][Full Text] [Related]
5. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
Håvik AB; Brandal P; Honne H; Dahlback HS; Scheie D; Hektoen M; Meling TR; Helseth E; Heim S; Lothe RA; Lind GE
J Transl Med; 2012 Mar; 10():36. PubMed ID: 22390413
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA
Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113
[TBL] [Abstract][Full Text] [Related]
8. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.
Sunwoo L; Choi SH; Park CK; Kim JW; Yi KS; Lee WJ; Yoon TJ; Song SW; Kim JE; Kim JY; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Chang KH
J Magn Reson Imaging; 2013 Feb; 37(2):351-8. PubMed ID: 23023975
[TBL] [Abstract][Full Text] [Related]
9. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
11. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A
JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793
[TBL] [Abstract][Full Text] [Related]
12. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
[TBL] [Abstract][Full Text] [Related]
13. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
14. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
15. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
[TBL] [Abstract][Full Text] [Related]
16. An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity.
Nguyen A; Legrain M; Noel G; Coca A; Meyer Ea N; Schott R; Lasthaus C; Chenard MP; Gaub MP; Lessinger JM; Guenot D; Entz-Werle N
Curr Cancer Drug Targets; 2015; 15(7):624-40. PubMed ID: 26118907
[TBL] [Abstract][Full Text] [Related]
17. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
[TBL] [Abstract][Full Text] [Related]
18. Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.
Kanemoto M; Shirahata M; Nakauma A; Nakanishi K; Taniguchi K; Kukita Y; Arakawa Y; Miyamoto S; Kato K
BMC Cancer; 2014 Aug; 14():641. PubMed ID: 25175833
[TBL] [Abstract][Full Text] [Related]
19. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
20. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC
Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]